IRVINE, Calif.--(BUSINESS WIRE)--Aug. 15, 2016--
Masimo
(NASDAQ:MASI) announced today that a new article published in The
Joint Commission Journal on Quality and Patient Safety reports on
the results of an expansion of the use of Masimo Patient SafetyNet™* to
more than 200 general floor beds at Dartmouth-Hitchcock Medical Center
(D-H) in Lebanon, New Hampshire.1 Patient SafetyNet is a
remote monitoring and clinician notification system that works in
conjunction with a variety of bedside monitors, such as Masimo Root®
with Radical-7® and Root with Radius-7®, powered
by Masimo SET® pulse oximetry – the first Measure-through
Motion and Low Perfusion™ pulse oximetry and the most accurate and
reliable pulse oximeter in such conditions according to over 50 studies.2
Masimo Patient SafetyNet was first implemented in the 36-bed orthopedic
unit at D-H in December 2007, as part of a surveillance strategy
supporting patient safety improvement. Clinicians reported that after 11
months, rescue events had been reduced by 65% and intensive care unit
transfers by 48%, and calculated annual cost savings of $1,480,000.3,4
They also announced that they had experienced zero preventable deaths or
instances of irreversible seizure brain damage due to opioids since
installation.4 As a result of the positive outcomes of the
pilot unit implementation, D-H expanded this continuous patient
monitoring approach, including the use of Patient SafetyNet, to
remaining post-surgical ward units in February 2009, to medicine ward
units in April 2010, and to the pediatric ward unit in February 2012.
Patients in more than 200 beds are now covered by D-H’s patient
surveillance system. As the authors note, “The original success in terms
of patient outcomes and enthusiastic endorsement by nurses prompted
request from other units for the system and led to the rapid spread of
the system across the institution.” The improvements first seen in the
pilot unit – in addition to the dramatic reductions in rescue events and
unplanned transfers, approximately two alarms per patient per 12-hour
nursing shift, and resolution of more than 85% of all alarm conditions
within 30 seconds and more than 99% before escalation was triggered –
have been “sustained over time in spite of increasing patient acuity (up
20% from 2010 to 2015) and unit occupancy (93% in 2015).”
Much of the initiative’s success is due to D-H’s development of a robust
general care alarm management strategy, including the implementation of
Masimo SET® Measure-through Motion and Low Perfusion™ pulse
oximetry. As the authors note, “device-level characteristics such as
measurement reliability and alarm annunciation” are critical. A
systematic approach to alarm management is needed because of the growing
problem of “‘alarm fatigue’ – the growing desensitization of health care
providers to alarms” as a result of the “growing number of monitoring
devices, combined with suboptimal patient monitoring and alarm
management strategies.” False and/or nonactionable alarms may occur as
much as 90% of the time, according to one study5; another,
involving the Philips HP Merlin M1094 monitor, found that 77% were
either not recognized or ignored6; a third, involving Nellcor
pulse oximetry, found an actual risk for patients in only 3% of alarm
states, and that anesthesiologists have been shown to disable alarms
because of high false alarm rates.7
D-H attempted to optimize several key elements of an effective alarm
management strategy: 1) static alarm settings – setting thresholds based
on patient groups to reduce nuisance alarms; 2) alarm delays –
introducing a delay of 15 seconds before an alarm sounds, as “Many
changes in physiologic parameters are brief and self-correcting”; 3)
alarm threshold adjustments – adapting to “physiologic variation among
different patients” by adjusting alarms based on a three-tiered system
of the static defaults, independent nurse adjustments, and
provider-ordered individualized settings; and 4) alarm announcement –
having the alarm sent to the nurse in charge of the patient via remote
pager and allowing customization of when and how alarms are escalated to
additional clinicians, by which practice alarm exposure has now been
reduced by almost 90%.
Important to the success of the D-H alarm management strategy was the
selection of Masimo SET® and Patient SafetyNet architecture,
as part of D-H’s patient surveillance system. As the authors note, a
fundamental factor affecting operation of and response to clinical
monitor alarms is “device-level characteristics such as measurement
reliability and alarm annunciation.” As the initiative’s
centrally-monitored parameter they notably chose oxygen saturation (SpO2),
measured using Masimo SET® pulse oximetry, which has been
shown to reduce false alarms by over 95% and increase true alarm
detection to over 97%, even during motion and low perfusion.8
Regarding the choice of remote monitoring system, the authors note that
“A previously installed multiparameter monitoring system on the
pediatric unit was largely rejected by the staff because of alarm system
issues, such as high false alarm rates, lack of directed notification,
and ambiguous alarm indicators. The alarm rate [with Masimo Patient
SafetyNet] was 75% lower than the alarm rate of the previous system
immediately following implementation of [Masimo Patient SafetyNet], and
100% of nursing staff survey respondents were in favor of continuing use
of [Masimo Patient SafetyNet]. The staff credited the robust alarm
management strategy and leadership rounding with the improved system
performance and high level of staff adoption.”
“Dartmouth-Hitchcock provides a compelling example of the benefits that
a robust patient monitoring and surveillance system, coupled with a
carefully executed strategy, can reap,” said Joe Kiani, Founder and CEO
of Masimo. “It is estimated that as many as 50,000 patients die each
year due to failure to rescue patients in the general ward.9
Any hospital that wants to eliminate general ward preventable deaths
should read both this article and Dartmouth-Hitchcock’s original study,
‘Impact of pulse oximetry surveillance on rescue events and intensive
care unit transfers: A before-and-after concurrence study,’ published in
2010.3 Together, they provide an excellent guide to
designing, implementing, and maintaining a successful hospital-wide
continuous monitoring system, as well as showcasing the innovative
practices that have arisen out of their focus on alarm management.
Dartmouth-Hitchcock’s success story, laid out in a well-executed plan
and follow on analysis over nearly a ten-year period, sets a powerful
precedent for other medical facilities: it’s time for all hospitals to
develop hospital-wide alarm management strategies and as part of that,
to implement Patient SafetyNet – to help save money and save lives.”
@MasimoInnovates
| #Masimo
References
-
McGrath, S.P., Taenzer, A.H., Karon, N, Blike, G. “Surveillance
Monitoring Management for General Care Units: Strategy, Design, and
Implementation.” The Joint Commission Journal on Quality and
Patient Safety. 2016 Jul;42(7):293-302.
-
All published clinical studies on Masimo products can be found at http://www.masimo.com/cpub/clinical-evidence.htm.
-
Taenzer A.H., Pyke J.B., McGrath S.P., Blike G.T. Anesthesiology.
2010 Feb;112(2):282-7.
-
Taenzer A, Blike G, McGrath S, Pyke J, Herrick M, Renaud C, Morgan J.
"Postoperative Monitoring - The Dartmouth Experience." Anesthesia
Patient Safety Foundation Newsletter Spring-Summer 2012. Available
online.
-
Imhoff M, Kuhls S. Alarm algorithms in critical care monitoring. Anesth
Analg. 2006;102:1525-1537.
-
Gorges M, et al. Improving alarm performance in the medical intensive
care unit using delays and clinical context. Anesth Analg.
2009;108:1546-1552.
-
Kestin IG, Miller BR, Lockhart CH. Auditory alarms during anesthesia
monitoring. Anesthesiology. 1988;69:106-109.
-
Shah N et al. J Clin Anesth 2012 Aug;24(5):385-91.
-
HealthGrades Quality Study. Patient Safety in American Hospitals (July
2004).
*The use of the trademark SafetyNet is under license from University
HealthSystem Consortium.
About Masimo
Masimo (NASDAQ:MASI) is a global leader in innovative noninvasive
monitoring technologies. Our mission is to improve patient outcomes and
reduce the cost of care by taking noninvasive monitoring to new sites
and applications. In 1995, the company debuted Masimo SET®
Measure-through Motion and Low Perfusion™ pulse oximetry, which has been
shown in multiple studies to significantly reduce false alarms and
accurately monitor for true alarms. Masimo SET® is estimated
to be used on more than 100 million patients in leading hospitals and
other healthcare settings around the world. In 2005, Masimo introduced
rainbow® Pulse CO-Oximetry technology, allowing noninvasive
and continuous monitoring of blood constituents that previously could
only be measured invasively, including total hemoglobin (SpHb®),
oxygen content (SpOC™), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), and more recently, Pleth Variability
Index (PVI®) and Oxygen Reserve Index (ORI™), in addition to
SpO2, pulse rate, and perfusion index (PI). In 2014, Masimo
introduced Root®, an intuitive patient monitoring and
connectivity platform with the Masimo Open Connect™ (MOC-9™) interface.
Masimo is also taking an active leadership role in mHealth with products
such as the Radius-7™ wearable patient monitor and the MightySat™
fingertip pulse oximeter. Additional information about Masimo and its
products may be found at www.masimo.com.
All published clinical studies on Masimo products can be found at http://www.masimo.com/cpub/clinical-evidence.htm.
Forward-Looking Statements
This press release includes forward-looking statements as defined in
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, in connection with the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements include, among others, statements regarding the potential
effectiveness of Masimo Patient SafetyNet™. These forward-looking
statements are based on current expectations about future events
affecting us and are subject to risks and uncertainties, all of which
are difficult to predict and many of which are beyond our control and
could cause our actual results to differ materially and adversely from
those expressed in our forward-looking statements as a result of various
risk factors, including, but not limited to: risks related to our
assumptions regarding the repeatability of clinical results; risks
related to our belief that Masimo's unique noninvasive measurement
technologies, including Masimo Patient SafetyNet, contribute to positive
clinical outcomes and patient safety; risks related to our belief that
Masimo noninvasive medical breakthroughs provide cost-effective
solutions with comparable accuracy and unique advantages, including:
immediate and continuous results that enable earlier treatment without
causing invasive trauma in all patients and in every clinical situation;
as well as other factors discussed in the "Risk Factors" section of our
most recent reports filed with the Securities and Exchange Commission
("SEC"), which may be obtained for free at the SEC's website at www.sec.gov.
Although we believe that the expectations reflected in our
forward-looking statements are reasonable, we do not know whether our
expectations will prove correct. All forward-looking statements included
in this press release are expressly qualified in their entirety by the
foregoing cautionary statements. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of
today's date. We do not undertake any obligation to update, amend or
clarify these statements or the "Risk Factors" contained in our most
recent reports filed with the SEC, whether as a result of new
information, future events or otherwise, except as may be required under
the applicable securities laws.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160815005359/en/
Source: Masimo
Masimo
Evan Lamb, 949-396-3376
elamb@masimo.com